Mustang Bio - MBIO STOCK NEWS

Mustang Bio (NASDAQ: MBIO), a clinical-stage biopharmaceutical firm, has announced CEO Manuel Litchman will participate in two investor conferences in New York City. The H.C. Wainwright 24th Annual Global Investment Conference will occur on September 12, 2022, featuring a corporate update and one-on-one meetings. A presentation will be webcasted for 30 days. Additionally, Mustang will engage in a panel at the Cantor Cell & Gene Therapy Conference on September 15, 2022. Mustang specializes in cell and gene therapies targeting various cancers and rare diseases.

Mustang Bio, Inc. (NASDAQ: MBIO) announced its financial results for Q2 2022, reporting a cash balance of $108.4 million, down from $123.2 million in Q1 2022. The company highlighted significant milestones, including favorable interim Phase 1/2 data for its CAR T therapy MB-106 for B-cell cancers, achieving an overall response rate of 96%. Additionally, FDA granted Orphan Drug Designation to MB-106 for Waldenstrom macroglobulinemia. R&D expenses increased to $15.2 million, with a net loss of $19.1 million for the quarter. Mustang anticipates advancing its gene therapy programs in 2023.

Mustang Bio (NASDAQ: MBIO) announced the successful administration of LV-RAG1, an ex vivo lentiviral gene therapy, to the first patient in a Phase 1/2 trial for treating RAG1-SCID, a severe genetic immunodeficiency. This significant milestone reflects the potential of MB-110, licensed from LUMC, to offer new hope for SCID patients. The treatment resulted in a functioning immune system, marking a positive development in Mustang's clinical pipeline. The company anticipates further advancements and plans to initiate a pivotal Phase 2 trial for MB-107 in the latter half of the year.

Mustang Bio has announced that the FDA has granted Orphan Drug Designation to MB-106, a CAR T cell therapy for Waldenstrom macroglobulinemia, a rare B-cell non-Hodgkin lymphoma. This designation provides benefits like tax credits and seven years of market exclusivity. The multicenter Phase 1/2 trial evaluating MB-106's safety and efficacy for relapsed/refractory B-NHL and CLL is now open for enrollment. Data presented at a recent congress showed a 96% overall response rate and a potential for outpatient administration, marking significant progress in addressing high unmet medical needs.

Mustang Bio, Inc. (NASDAQ: MBIO) announced promising interim data from a Phase 1/2 clinical trial of MB-106, a CD20-targeted CAR T cell therapy for relapsed or refractory B-NHLs and CLL. The therapy demonstrated a 94% overall response rate and a 78% complete response rate in patients with follicular lymphoma. Additionally, it achieved a 100% overall response rate in other B-cell malignancies. The trial showcases a favorable safety profile, making MB-106 a viable outpatient treatment option. Enrollment for the study remains open.

Mustang Bio (NASDAQ: MBIO) has announced encouraging interim results from a Phase 1/2 clinical trial for its gene therapy MB-107, aimed at treating X-linked severe combined immunodeficiency (XSCID). The trial included 23 infants, all of whom are alive and have shown complete hematopoietic recovery without signs of malignant transformation at a median follow-up of 2.6 years. The company plans to initiate a pivotal Phase 2 trial later this year, further validating the therapy's safety and efficacy.

Mustang Bio, Inc. (NASDAQ: MBIO) reported financial results for Q1 2022, revealing a net loss of $19.8 million ($0.20 per share), up from $15.0 million ($0.19 per share) a year earlier. As of March 31, 2022, cash reserves rose to $123.2 million, an increase of $12.6 million year-to-date. Significant clinical data were presented at major conferences, showing a 96% overall response rate for MB-106 in B-cell NHL and CLL. Upcoming presentations are scheduled for EHA2022 and ASGCT. Mustang aims to start several clinical trials for MB-106 and MB-107 later this year, reflecting strong progress in its development pipeline.

Mustang Bio (MBIO) announced results from the Phase 1/2 trial of MB-106, a CD20-targeted CAR T cell therapy for relapsed or refractory follicular lymphoma (FL), to be presented at EHA2022. Dr. Mazyar Shadman will provide updated patient data, indicating a favorable safety profile and notable response rates. The trial is progressing with expanding enrollment criteria, which includes CAR T naïve patients and those previously treated. Mustang anticipates dosing the first patient in a multicenter trial evaluating MB-106's safety and efficacy this quarter.

Mustang Bio announced significant interim Phase 1/2 clinical trial results for its lentiviral gene therapy, MB-107, targeting X-linked severe combined immunodeficiency (XSCID). The data highlights a cohort of 23 infants, all still alive, with 20 showing recovery from pre-existing infections and normal growth. Seventeen of 18 patients with over six months of follow-up achieved robust immune reconstitution. The presentation will be held at the ASGCT Annual Meeting on May 19, 2022, with plans to initiate a pivotal Phase 2 trial later in 2022.